BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years

Nazneen Rahman(Institute of Cancer Research), Helen Hanson(University of Exeter), Richard S. Houlston(Institute of Cancer Research), Clare Turnbull(Institute of Cancer Research), Imran Howell(Institute of Cancer Research), Stephen A. Butler(St George's, University of London), Deborah Hughes(Institute of Cancer Research), Susan Shanley(Royal Marsden NHS Foundation Trust), Gill Ross(Royal Marsden NHS Foundation Trust), Lindsay B. Robertson(Institute of Cancer Research), D. Gareth Evans(Manchester Academic Health Science Centre), Andrew Tutt(Institute of Cancer Research), S. Seal(Institute of Cancer Research), Margaret Warren-Perry(Institute of Cancer Research), Diana Eccles(Princess Anne Hospital)
British Journal of Cancer
February 14, 2012
10.1038/bjc.2012.31
Cited by 98

Related Papers

Genome-wide association study identifies novel breast cancer susceptibility loci
|Nature|2007|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Mutational Processes Molding the Genomes of 21 Breast Cancers
|Cell|2012|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k